Medlior Publications

Click the topics below to explore Medlior’s publications, including RWE and Evidence Synthesis studies.

  • Lachance CC, Darvesh N, McGill SC, Butcher R, Gates M, Kim J, Nayakarathna R. Virtual care rapid scoping: main report. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 December (CADTH Health Technology Review). Read more.

 

  • Nayakarathna R, Neilson H, MacDougall D, Cowling T. Virtual care use in primary care or specialty care settings. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 August (CADTH Health Technology Review). Read more.

 

  • Cowling T, Neilson H, Nayakarathna R, Mahood Q. Low-dose ipilimumab in combination with nivolumab or pembrolizumab for the treatment of advanced melanoma. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 July (CADTH Health Technology Review). Read more.

 

  • Longstaff W, Filkowski J, Severn M. CADTH Health Technology Review: The Small House Model to Support Older Adults in Long-Term Care. Canadian Journal of Health Technologies, 2022. Read more.

 

  • Cowling T, Graves E, Loshak H. Canadian Agency for Drugs and Technologies in Health (CADTH) Emerging Health Technology for COVID-19: Virus-neutralizing monoclonal antibodies against SARS-CoV-2. Ottawa: CADTH; 2020 Dec. (CADTH Horizon Scan Report). Read more.

 

  • Cowling T, Loshak H. An Overview of Liquid Biopsy for Screening and Early Detection of Cancer. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Nov. (CADTH Issues in Emerging Health Technologies; Issue). Read more.

 

  • Cowling T, Farrah K. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 May (CADTH rapid response report: summary with critical appraisal). Read more.

 

  • Cowling T, Frey N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults Undergoing Magnetic Resonance Imaging: A Review of Safety Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Mar. (CADTH rapid response report: summary with critical appraisal). Read more.

 

  • Cowling T, Jones S. Gene therapy: international regulatory and health technology assessment (HTA) activities and reimbursement status. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2018. (Environmental scan; no. 71) Read more.

 

  • Cowling T, Dolcine B. Point-of-care testing. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Oct. (Environmental scan; no. 65).

 

  • Cowling T, Jones S. Topical antibiotics for infected wounds: A review of the clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Mar. (CADTH rapid response report: summary with critical appraisal). Read more.

 

  • Pant S, Cowling T, Chelak K, Kaunelis D. Opioid formulations with tamper-resistance or abuse-deterrent features — products and policies. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017. (Environmental scan; no. 62).

 

  • Cowling T, Pant S. Single drug technology assessment processes across health technology assessment organizations. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2016 Nov. (Environmental Scan; Issue 55). Read more.

 

  • Cowling T, Boucher M. (2016). Environmental Scan on Pharmaceuticals Requiring Companion Diagnostics. International Journal of Technology Assessment in Health Care. 32(5), 327-336. Read more.

 

  • Cowling T, de Léséleuc L. Surgical interventions performed outside the hospital operating room. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2015. (Environmental Scan; Issue 49). Read more.

 

  • Cowling T, de Léséleuc L. Reprocessing of single-use medical devices: a 2015 update. [Environmental Scan; Issue 48]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015. Read more.

 

  • Loorand-Stiver L, Cowling T, Perras C. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Ottawa; Canadian Agency for Drugs and Technologies in Health (CADTH); 2013 Oct [updated 2016 Feb]. (Environmental scan; issue 42). Read more.

 

  • Vegesna A, Tran M, Angelaccio M, Arcona S. Remote patient monitoring via non-invasive digital technologies: A systematic review. Telemedicine and e-Health. 2017;23(1):3-17. Read more. (Medlior acknowledged for writing).

 

  • Morrison P, Wang G, Estes M, Sharif B, Shaw E, Cowling T, Tay J, Jimenez-Zepeda VH, Far b, Amannejad Y. Toward Standardized Structured Reporting for the Management of Multiple Myeloma in Alberta: Insights in Application of Machine Learning. Presented at the 2020 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium (e-poster Gallery). Read more and view here.

 

  • Chen G, Farris M, Cowling T. Methodological issues for measuring pharmacotherapy treatment and its calibration with patient outcomes using real-world data. International Journal Population Data Science. 2018; 3:3: 170. Read More.

 

  • Zhou H, Taber C, Arcona S, Li Y. Difference-in-differences method in comparative effectiveness research: Utility with unbalanced groups. Appl Health Econ Health Policy. 2016;14:419-29. Read More. (Medlior acknowledged for writing).

 

  • Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Haddad P. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Multiple Sclerosis and Related Disorders 2017; 18(Supplement C): 218-24. Read More.

 

  • Gerber B, Cowling T, Chen G, Rivest D, Yeung M, Duquette P, Kindudu C, Barbeau M & Haddad P. The Impact of Treatment Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: Real-World Evidence from Alberta, Canada [Abstract]. Value in Health. Nov 2016; 19(7): page A437.

 

  • Gerber B, Cowling T, Chen G, Haddad P. Linking Administrative Data Sets from Alberta, Canada to Examine the Impact of Treatment Adherence on Health Care Resource Utilization Among Multiple Sclerosis Patients. Presented at the 2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, April 2017; Ottawa, Canada. Read More.

 

  • Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Schecter R, & Haddad P. MS patient characteristics and healthcare resource utilization from administrative databases: real-world evidence from Alberta, Canada. Presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Sept 2016; London, UK. Read More.

 

  • Larkin-Kaiser K, Waters-Banker C, Cowling T, Snow L.A., Hasani I, Fernet M. Canadian Real-World Evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis: a systematic literature review. Value in Health, Volume 22, S707. Read More.

 

  • Oliveira T, Brown J, Juby A.G. Schneider P, Wani R.J. Packalen M, Avcil S, Li S, Farris M, Graves E, McMullen S & Kendler D.L. Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada. Arch Osteoporosis. 2022; 17(110).

 

  • Oliveira T, Kendler D.L, Schneider P, Juby A.G., Wani R.J., Packalen M, Avcil S, Li S, Waters-Banker C, Graves E, McMullen S & Brown J. Trends in osteoporotic fracture and related in-hospital complications during the COVID-19 pandemic in Alberta, Canada. Arch Osteoporosis. 2022; 17(109).

 

  • Mackinnon ES, Anderson T, Raggi P, Gregoire J, Wani RJ, Packalen MS, Graves E, Ekwaru P, McMullen S, Goodman SG. Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada. CJC Open. 2023 Jun 22.  Read More.

 

  • Mackinnon ES, Har B, Champsi S, Wani RJ, Geyer L, Shaw E, Farris MS, Anderson TJ. Guideline LDL-C threshold achievement in acute myocardial infarction patients: A real-world evidence study demonstrating the impact of treatment intensification with PCSK9i. Cardiology and Therapy. 2023; 12:327-38.

 

  • Mackinnon ES, Anderson TJ, Raggi P, Gregorie JC, Wani R, Packalen M, Oliveira T, Li S, McMullen S, Cowling T, Goodman SG. Trends in Major Adverse Cardiac Events During the COVID-19 Pandemic in Alberta, Canada. American Heart Association Scientific Sessions 2021, November 13-15, 2021 (Virtual). Read More and More.

 

  • Goodman SG, Mackinnon ES, Gregorie JC, Raggi P, Wani R, Packalen M, Avcil S, Farris MS, Graves E, Cowling T, Anderson TJ. COVID-19 Pandemic Induced Disruptions in Troponin and Low-Density Lipoprotein Cholesterol Laboratory Test Volumes Across Alberta. Canadian Congress of Cardiology, October 20-23, 2021 (Virtual). Read More.

 

  • Chen G, Farris MS, Cowling T, Pinto L, Rogoza R, MacKinnon E, Champsi S, Anderson TJ. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study. Clin Cardiol. 2021 Read More. 

 

  • Rogoza R, Oh P, Goeree R, Goodman S, Fairbairn M, Mackinnon E, Pericleous L, Motsepe-Ditshego P, Anderson T. Patterns of low-density lipoprotein cholesterol management and goal attainment in patients with atherosclerotic cardiovascular disease aged 65 years and older from Alberta and Ontario. Presented at: Canadian Cardiovascular Congress 2020; October 22-25, 2020; Virtual.  Read More. (Medlior acknowledged for data analysis).

 

  • Scory T, Chen G, Farris M, Shih YH, Pinto L, Cowling T. Lipid-lowering therapy patterns and low-density lipoprotein-cholesterol management among patients with acute myocardial infarction in Alberta, Canada. American College of Cardiology (ACC).20/World Congress of Cardiology (WCC) Virtual; March-June 2020; Read More.

 

  • Chen G, Sharif B, Farris M, Cowling T, Pinto L, Rogoza R, Fairbarin M, Anderson T. Healthcare resource utilization and associated costs among patients with atherosclerotic cardiovascular diseases in Alberta, Canada. Canadian Journal of Cardiology 2020;30(10): S20. Read More.

 

  • Chen G, Farris M, Cowling T, Colgan SM, Xiang P, Pericleous L, Rogoza RM, Tai M, Anderson T. Treatment and Low-density Lipoprotein Cholesterol management in patients diagnosed with clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology 2019;35(7):884-891. Read More.

 

  • Chen G, Farris M, Cowling T, Tai M, Pinto L, Colgan S, Rogoza RM, Anderson TJ. Low-density Lipoprotein Cholesterol Management in Patients with Atherosclerotic Cardiovascular Diseases and Pre-existing Diabetes in Alberta, Canada. American Diabetes Association (ADA) 79th Scientific Sessions 2019; June 8, 2019; San Francisco, California. Read more.

 

  • Chen G, Farris MS, Cowling T, Colgan S, Xiang P, Pericleous L, Rogoza RM, Anderson TJ. Atherosclerotic Cardiovascular Diseases and Low-Density Lipoprotein Cholesterol Management in Alberta, Canada. Circulation. 2018;138:A142-72.  Read More.

 

  • Senior P, Goldenberg R, Demchuk A, Klimek-Abercrombie A, Mau G, Moura CS, Filkowski J, Connelly K. Real-world use of guideline-directed cardioprotective therapy in type 2 diabetes mellitus with atherosclerotic cardiovascular disease: A retrospective cohort analysis using administrative health data in Alberta, Canada. Presented at: Vascular 2023; October 27, 2023; Montreal, Canada.

 

  • Senior P, Hahn J, Mau G, Manivong P, Shaw E. Evidence of clinical inertia from a retrospective cohort analysis of basal insulin initiation in type 2 diabetes mellitus in a Canadian cohort using administrative health data in Alberta, Canada. Presented at: Vascular 2023; Montreal, Canada.

 

  • Hawes C, Harris S, Mubarack F, Hinds D, Cowling T, Waters-Banker C, Farris M, About-Setta A. Comparative effectiveness and safety, and health-related quality of life of haemophilia A treatments: A systematic review. (2020), Abstracts. Haemophilia, 26: 27-181. The European Association for Haemophilia and Allied Disorders (EAHAD)  Read More and view on Medlior.

 

  • Lau D, Shaw E, McMullen S, Cowling T, Witges K, Amitay E, Steubl D, Girard L. WCN23-0604 Acute and chronic complication profiles among patients identified with chronic kidney disease in Alberta, Canada. Kidney International Reports. 2023;8(3):S174. Read More.

 

  • Graves EB, Gerber BR, Berrigan PS, Shaw E, Cowling TM, Ladouceur MP, Bougie JK. Epidemiology and treatment utilization for Canadian patients with migraine: a literature review. Journal of International Medical Research. 2022;50(9). Read More.

 

  • Ismail Z, Wilson M, Khalifa H, Belovich D, Shaw E, Pham T, McMullen S, Chen Y, Sadman N, Cai J, Zulkermine F, Barber D. Use of natural language processing to examine real-world clinical practice patterns in patients with dementia and Alzheimer’s disease in one primary care practice in Ontario, Canada. Presented at: 11th Canadian Conference on Dementia; November 2-4, 2023; Toronto, Canada.

 

  • McMullen S, Graves E, Ekwaru P, Pham T, Mayer M, Ladouceur MP, Hubert M, Bougie J, Amooozegar F. Burden of episodic migraine, chronic migraine, and medication overuse headache in Alberta. Can J Neurol Sci, 1-11. 2023. Read More.

 

  • Graves, E, Cowling, T, McMullen, S, Ekwaru, P, Pham, T, Mayer, M, Ladouceur, MP, Hubert, M, Bougie, J, Amoozegar, F (2023). Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada. Can J Neurol Sci, 1-11. Read More.

 

  • Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Budd N, Maturi B, Cowling T Mestre TA. Epidemiology and economic burden of Huntington’s Disease: a Canadian provincial public health system perspective, Journal of Medical Economics. 2022;25(1):212-9. Read More.

 

  • Budd N, Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Maturi B, Cowling T, Mestre TA. Disease Burden of Huntington’s Disease in a Canadian Setting Using Administrative Health Data. The 28th Annual Meeting of the Huntington Study Group (HSG 2021), November 4-6 (Virtual). Read More.

 

  • Budd N, Mestre T, Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu J, Maturi B, Cowling T. Evaluation of Health-Related Quality of Life for Individuals with Huntington’s Disease and Care Partners in Canada. International Congress of Parkinson’s Disease and Movement Disorders (MDS) Congress 2021, September 17-22 (Virtual). Read More

 

  • McMillan HJ, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmüller H. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553-568. Read More

 

  • Chen G, Sharif B, Gerber B, Farris MS, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK.(2021) Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada, Journal of Medical Economics, 24:sup1, 51-59. Read More

 

  • McMillan H, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmuller H. Disease and treatment burden of spinal muscular atrophy on patients and caregivers in Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal Read More.

 

  • Chen G, Sharif B, Gerber B, Farris M, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK. A population-based study examining the epidemiologic burden, healthcare resource utilization and costs of spinal muscular atrophy in Alberta, Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal Read More.

 

  • Cowling T, Nayakarathna R, Wills AL, Tankala D, Paul Roc N, Barakat S. Early access for innovative oncology medicines: a different story in each nation. J Med Econ. 2023 Jan-Dec;26(1):944-953. Read more.

 

  • Nakagawa K, Matsumura K, Scory T, Farris M, Larkin-Kaiser KA, Kikkawa H, Ivanova JI, Wilner KD. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population. Future Oncology. 2020. Read More.

 

  • Larkin-Kaiser K, Scory T, Farris M, Wilner K, Ivanova J. PCN14 Updated Network Meta-analysis of First-line EGFR-targeted Tyrosine Kinase Inhibitor Treatments for Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR-activating Mutations. Value in Health. 2020;23(Supplement 1): S24. Read More.

 

  • Nakagawa K, Matsumura K, Larkin-Kaiser KA, Scory T, Farris M, Kikkawa H, Ivanova J, Wilner K. Indirect Analysis of First-line Tyrosine Kinase Inhibitors for EGFR+ NSCLC in Japanese patients. Presented at: 61st Annual Meeting of the Japan Lung Cancer Society; 2020; Okayama, Japan.

 

  • Farris M, Larkin-Kaiser KA, Scory T, Boyne D, Wilner KD, Pastel M, Cappelleri JC, Ivanova JI. Network meta-analysis of first-line therapy for advanced EGFR mutation-positive non-small-cell lung cancer: updated overall survival. Future Oncology.2020; 16(36):3107-116. Read More.

 

  • Franek J, Cappelleri JC, Larkin-Kaiser KA, Wilner KD, Sandin R. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncology. 2019;15(24):2857-71. Read more and more.

 

  • Farris M, White K, Liu FF, Cowling T. A Rapid Literature Review of Real-World Evidence in Multiple Myeloma: Patient Characteristics and Health Outcomes. Presented at The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2018, November 2018; Barcelona, Spain. Read more.

 

  • Jimenez-Zepeda VH, Chen G, Cowling T, Shaw E, Farris M, Liu FF, Tay J. Multiple Myeloma Treatment Landscape from 2011 to 2017 in Alberta, Canada: Results from the Population-Based “Identifying Outcomes in Real-World Multiple Myeloma” (INFORMM) Study. Presented at the 24th Congress of the European Hematology Association (EHA); June 13–16, 2019; Amsterdam, Netherlands. Read more.

 

  • Shaw E, Liu F, Tay J, Jimenez-Zepeda VH, Chen G. Identifying Outcomes in Real-World Multiple Myeloma (INFORMM): Insights in Methodology for Using Administrative Health Data in Alberta. Presented at the 2019 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium; April 14–16, 2019; Edmonton, AB, Canada. Read more and more.

 

  • Tay J, Chen G, Cowling T, Shaw E, Farris M, Liu F F, Victor H. Jimenez-Zepeda Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study. Accepted for the 2019 ASCO Annual Meeting. Journal of Clinical Oncology 37, 2019 (suppl; abstr e19509) Read more and more.

 

  • St Michael’s Hospital, Medlior, WSIB, Dr. S Tarlo, Dr. A Lau and Dr. A Adisesh. Chronic obstructive pulmonary disease – Discontinuation of smoking offset for non-economic loss benefits.  Causes, diagnosis, and profession of COPD following workplace exposure to vapours, gases, dust and fumes ; February 2021; Read More.

 

  • Hawkins NM, Nordon C, Rhodes K, Talukdar M, McMullen S, Ekwaru P, Pham T, Randhawa AK, Sin DD. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart. 2024 (In Press)

 

  • Parsekar K, Kossack N, Hernández I, Vogelmeier CF, Kolb N, Baak BN, Swart KMA, Simons SO, Bengtsson C, Vojinovic D, Sin DD, Hawkins NM, McMullen S, Pham T, García CC, Martínez N, Hernández JSC, Abram M, Halbach M, van Burk L, Randhawa A, Nordon C. Healthcare resource utilisation and costs in patients experiencing severe cardiac events following a COPD exacerbation: results from EXACOS-CV studies in Spain, Germany, the Netherlands and Canada. Presented at: ISPOR Europe 2023; November 12-15, 2023; Copenhagen, Denmark.

 

  • Ramsahai JM, Randhawa A, Foster A, Geyer L, McMullen S. The risk of exacerbation with elevated biomarkers, and real-world biomarker variability, in patients with severe asthma: A retrospective population-based study. Presented at: CHEST 2023; October 8-11, 2023; Honolulu, USA.

 

  • Bhutani M, Talukdar M, Randhawa A, Manivong P, Gelfand A, McMullen S, Mayers I. Short-acting beta agonist (SABA), antibiotics, oral corticosteroid (OCS) and risk of mortality and cardiopulmonary events in patients with chronic obstructive pulmonary disease (COPD). Presented at: CHEST 2023; October 8-11, 2023; Honolulu, USA.

 

  • Vogelmeier C, Simons SO, Garbe E, Sin DD, Hawkins NM, Manito N, Santos S, Polinder K, Lobier M, Ekwaru P, Kossack N, Hernandez I, Mullerova H, Randhawa A, van Burk L, Sanchez-Covisa J, Rhodes K, Nordon C on behalf of the EXACOS-CV study group. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Presented at: ERS Congress 2023; September 9-13, 2023; Milan, Italy.

 

  • Licskai C, Kayaniyil S, Hussey A, Manivong P, McMullen S, Ferrone M, Talukdar M. Regional variation of COPD burden in Alberta, Canada. Presented at: European Respiratory Society International Congress; September 9-13, 2023; Milan, Italy.

 

  • Hawkins N, Vogelmeier CF, Simons SO, Garbe E, Manito N, Swart KMA, Ekwaru P, Kossack N, Hernandez I, Mullerova H, Randhawa A, van Burk L, Sanchez-Covisa J, Rhodes K, Nordon C on behalf of the EXACOS-CV study group. Increased risk of decompensated heart failure, acute coronary syndrome, arrhythmias and ischaemic stroke following exacerbations of COPD: results from a multi-database cohort study. Presented at: ESC Congress 2023; August 25-28, 2023; Amsterdam, Netherlands.

 

  • Ramsahai JM, Randhawa A, Geyer L, Robert N, Manivong P, Shephard C, Foster A, Gelfand A, Graves E, McMullen S. A population-based study of severe asthma exacerbations and symptom control in Alberta, Canada. Presented at: Canadian Respiratory Conference; April 20-22, 2023; Montreal, Canada.

 

  • Bhutani M, Randhawa A, Talukdar M, Manivong P, Fearon D, Gelfand A, Graves E, McMullen S, Mayers I. Associations between medication use, exacerbations, and healthcare utilization in COPD: a population-based study. Presented at: Canadian Respiratory Conference; April 20-22, 2023; Montreal, Canada.

 

  • Ramsahai JM, Randhawa A, Shephard C, Foster A, Geyer L, Manivong P, Graves E, McMullen S. A population-based study of the burden of severe asthma in Alberta, Canada. Can J Respir Crit Care Sleep Med. 2023;7(4):192-200. Read More.

 

  • Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE. Treatment patterns and costs for anti-TNF-alpha biologic therapy in patients with psoriatic arthritis. BMC Musculoskeletal Disorders. 2016;17:261. Read More. (Medlior acknowledged for writing).